tbuckley/cabot-search huggingface dataset:
Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma
Authors: Chong Hyun Suh, Ho Sung Kim, Sung Soo Ahn, Minjung Seong, Kichang Han, Ji Eun Park, Seung Chai Jung, Choong Gon Choi, Sang Joon Kim, Sang Min Lee, Jeong Hoon Kim, Seung-Koo Lee, Seung Hong Choi, Sung Tae Kim, Lakshmi Nayak, Tracy T Batchelor, Raymond Y Huang, Jeffrey P Guenette
Journal: Neuro-Oncology (2021)

We aimed to investigate the detection rate of body CT or PET/CT for sites of extracranial disease in patients with a new pathological diagnosis of CNS DLBCL and to identify factors associated with sites of extracranial disease.An international multicenter cohort study of consecutive immunocompetent patients with a new diagnosis of CNS DLBCL confirmed by brain biopsy who underwent CT and/or PET/CT to evaluate for sites of extracranial disease between 1998 and 2019. The primary outcome was the detection rate of extracranial lymphoma by CT or PET/CT. Subgroup analyses according to age and EBV status were also performed. Logistic regression analyses were performed to determine factors related to sites of extracranial disease. Detection rates of CT and PET/CT were compared.One thousand and forty-three patients were included. The overall detection rate of CT or PET/CT was 2.6% (27/1043). The treatment approach was adjusted in 74% of these patients. Multivariable analysis demonstrated that age >61 years (OR, 3.10; P = .016) and EBV positivity (OR, 3.78; P = .045) were associated with greater odds of extracranial lymphoma. There was no statistically significant difference in detection rate between CT and PET/CT (P = .802). In patients ≤61 years old, the false-referral rates were significantly higher than the detection rates (P < .001).Our results showed increased odds of extracranial lymphoma in patients with older age or EBV-positive lymphoma. Treatment was adjusted in a majority of patients diagnosed with extracranial lymphoma, thereby supporting the current guidelines for the use of contrast-enhanced body CT or PET/CT in patients with newly diagnosed CNS DLBCL.
992P Pan-cancer T-cell priming transcriptomic markers reveals interpatient immunomic heterogeneity independent of histologic type
Authors: H. Miyashita, R. Kurzrock, S. Lee, N. Bevins, S. Pabla, M. Nesline, S. Glenn, J. Conroy, P. DePietro, S. Kato
Journal: Annals of Oncology (2021)
Abstract 13277: Beneficial effects on Aerobic Capacity and Threshold Heart Rate for Arrhythmias from Exercise Training in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia
Authors: Ravinea Manotheepan, Jörg Saberniak, Tore K Danielsen, Thor Edvardsen, Ivar Sjaastad, Kristina H Haugaa, Mathis K Stokke
Journal: Circulation (2012)

Background Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) have an increased risk of ventricular arrhythmias (VA) triggered by exercise. During exercise testing, these ar...
Silencing of the ras association domain family protein 1, isoform C (RASSF1C) inhibits cancer cell growth
Authors: Yousef Amaar, Marlon Minera, Laurice Hatran, Subburaman Mohan, Donna Strong, Mark E. Reeves
Journal: Cancer Research (2006)

2653  Background Recently, the RASSF1 gene has been identified as a Ras effector encoding two major mRNA forms, RASSF1A and RASSF1C, derived by alternative promoter selection and alternative mRNA splicing. RASSF1A is a tumor suppressor. Over-expression studies have suggested that RASSF1C may also act as a tumor suppressor in prostate cancer LNCAP and renal cell carcinoma KRC/Y cells. However, the function of RASSF1C in both normal and cancer cells is still unknown. In order to learn about the function of RASSF1C in human cancer cells, we have tested the effect of silencing RASSF1C mRNA using siRNA in breast, lung, and prostate cancer cell lines that express RASSF1C but not RASSF1A. Procedures Cancer cell lines (Breast: MDA-MB231, T47D, Lung: NCI H1299, Prostate: LNCAP) were transfected with either a small interfering RNA (siRNA) specific for RASSF1C (siRNA-1C) or a control plasmid. Expression of RASSF1C mRNA was then quantitated with RT-PCR. Proliferation of cells transfected with siRNA-1C or control was measured using the Alamar Blue assay. RASSF1C over-expression studies were also carried out in the cancer cell lines using either an Xi-RASSF1C expression plasmid or control plasmid. Results Over-expression of siRNA-1C from a pSilencer vector reduced RASSF1C mRNA levels compared to controls in all cancer cell lines. In addition, reduction of RASSF1C expression caused a significant decrease in cell proliferation in all cancer cell lines. These findings are consistent with those that we observed when RASSF1C mRNA is silenced in multiple osteosarcoma cell lines. In addition, over-expression of RASSF1C in the lung cancer cell line NCI H1299 increased cell proliferation while RASSF1C over-expression in the prostate cancer cell line LNCAP decreased cell proliferation. Conclusions Our siRNA findings suggest that RASSF1C is not a tumor suppressor, but rather stimulates cell proliferation. This is unexpected based on previous findings that RASSF1C may be a tumor suppressor. Our over-expression findings appear to suggest that when over expressed, RASSF1C may mimic RASSF1A functions in the presence of specific effectors in certain tissues such as the prostate.
783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9
Authors: A. Oaknin, B.J. Monk, I. Vergote, A.C. de Melo, Y.M. Kim, A. Lisyanskaya, V. Samouëlian, H.S. Kim, E.A. Gotovkin, F. Damian, C-L. Chang, S. Takahashi, J. Li, M. Mathias, M.G. Fury, C. Ivanescu, M. Reaney, J. Harnett, C-I. Chen, K.S. Tewari
Journal: Annals of Oncology (2021)
Update on SARS-CoV-2 seroprevalence: regional and worldwide
Authors: Ali Rostami, Mahdi Sepidarkish, Aylar Fazlzadeh, Ali H. Mokdad, Aida Sattarnezhad, Sahar Esfandyari, Seyed Mohammad Riahi, Abolfazl Mollalo, Mohammadreza Esmaeili Dooki, Masomeh Bayani, Maryam Nazemipour, Mohammad Ali Mansournia, Peter J. Hotez, Robin B. Gasser
Journal: Clinical Microbiology and Infection (2021)

With limited vaccine supplies, an informed position on the status of SARS-CoV-2 infection in people can assist the prioritization of vaccine deployment.We performed a systematic review and meta-analysis to estimate the global and regional SARS-CoV-2 seroprevalences around the world.We systematically searched peer-reviewed databases (PubMed, Embase and Scopus), and preprint servers (medRxiv, bioRxiv and SSRN) for articles published between 1 January 2020 and 30 March 2021.Population-based studies reporting the SARS-CoV-2 seroprevalence in the general population were included.People of different age groups, occupations, educational levels, ethnic backgrounds and socio-economic status from the general population.There were no interventions.We used the random-eﬀects meta-analyses and empirical Bayesian method to estimate the pooled seroprevalence and conducted subgroup and meta-regression analyses to explore potential sources of heterogeneity as well as the relationship between seroprevalence and socio-demographics.We identified 241 eligible studies involving 6.3 million individuals from 60 countries. The global pooled seroprevalence was 9.47% (95% CI 8.99-9.95%), although the heterogeneity among studies was significant (I2 = 99.9%). We estimated that ∼738 million people had been infected with SARS-CoV-2 (as of December 2020). Highest and lowest seroprevalences were recorded in Central and Southern Asia (22.91%, 19.11-26.72%) and Eastern and South-eastern Asia (1.62%, 1.31-1.95%), respectively. Seroprevalence estimates were higher in males, persons aged 20-50 years, in minority ethnic groups living in countries or regions with low income and human development indices.The present study indicates that the majority of the world's human population was still highly susceptible to SARS-CoV-2 infection in mid-2021, emphasizing the need for vaccine deployment to vulnerable groups of people, particularly in developing countries, and for the implementation of enhanced preventive measures until 'herd immunity' to SARS-CoV-2 has developed.
Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease
Authors: Philip Greenland, Donald M. Lloyd-Jones
Journal: JAMA Cardiology (2021)

Current guidelines recommend a few different approaches to the use of coronary artery calcium (CAC) testing as a tool for risk assessment and decision-making regarding drug therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD).Coronary artery calcium testing is not recommended for universal screening, particularly in patients at very low or high predicted risk for ASCVD, where its yield and utility for altering clinical decisions are limited. Use of CAC testing appears to be optimal when used in selected patients who are at intermediate or borderline risk of ASCVD as a sequential decision aid after initial quantitative risk assessment and consideration of individual patient risk-enhancing factors (eg, strong family history of premature ASCVD, chronic kidney disease). Although convincing clinical trials have not been completed, observational studies strongly suggest that, in those at intermediate risk, CAC testing can meaningfully reclassify risk and can support improved targeting of drug therapy to patients most likely to benefit.This narrative review summarizes the evidence available about the appropriate role of CAC testing for ASCVD risk assessment. Coronary artery calcium testing should be used selectively in patients who are at intermediate risk of ASCVD, when there is persistent uncertainty after performing standard risk assessment using traditional risk factors in a risk score, and after consideration of additional individual risk-enhancing factors. In these situations, the result of the CAC test can be helpful to clarify whether the patient's true risk is high enough to justify initiation of primary prevention medications, such as statins or aspirin.
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data
Authors: Ruitian Gao, Shuai Zhao, Kedeerya Aishanjiang, Hao Cai, Ting Wei, Yichi Zhang, Zhikun Liu, Jie Zhou, Bing Han, Jian Wang, Han Ding, Yingbin Liu, Xiao Xu, Zhangsheng Yu, Jinyang Gu
Journal: Journal of Hematology & Oncology (2021)

Abstract Background Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is challenging and subjective. This study aims to build an automatic diagnostic model for differentiating malignant hepatic tumors based on patients’ multimodal medical data including multi-phase contrast-enhanced computed tomography and clinical features. Methods Our study consisted of 723 patients from two centers, who were pathologically diagnosed with HCC, ICC or metastatic liver cancer. The training set and the test set consisted of 499 and 113 patients from center 1, respectively. The external test set consisted of 111 patients from center 2. We proposed a deep learning model with the modular design of SpatialExtractor-TemporalEncoder-Integration-Classifier (STIC), which take the advantage of deep CNN and gated RNN to effectively extract and integrate the diagnosis-related radiological and clinical features of patients. The code is publicly available at https://github.com/ruitian-olivia/STIC-model . Results The STIC model achieved an accuracy of 86.2% and AUC of 0.893 for classifying HCC and ICC on the test set. When extended to differential diagnosis of malignant hepatic tumors, the STIC model achieved an accuracy of 72.6% on the test set, comparable with the diagnostic level of doctors’ consensus (70.8%). With the assistance of the STIC model, doctors achieved better performance than doctors’ consensus diagnosis, with an increase of 8.3% in accuracy and 26.9% in sensitivity for ICC diagnosis on average. On the external test set from center 2, the STIC model achieved an accuracy of 82.9%, which verify the model’s generalization ability. Conclusions We incorporated deep CNN and gated RNN in the STIC model design for differentiating malignant hepatic tumors based on multi-phase CECT and clinical features. Our model can assist doctors to achieve better diagnostic performance, which is expected to serve as an AI assistance system and promote the precise treatment of liver cancer.
Consider prioritising homeless people on waiting lists to improve their health, says NICE
Authors: Ingrid Torjesen
Journal: BMJ (2021)

Health and social care services need to work harder to improve the health of homeless people by considering prioritising them on waiting lists, offering them vouchers to engage with services, and not deregistering them for missing appointments, says a draft guideline from the National Institute for Health and Care Excellence.1

The guideline, which was developed with the Centre for Homelessness Impact, seeks to tackle the significant health inequalities and poor health outcomes among homeless people. Mortality among people experiencing homelessness is around 10 times higher than in the general population, and life expectancy is around 30 years less, with many deaths from preventable causes.

The homeless population, which includes people living …
1575P Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two UK waves of the COVID-19 pandemic at University College London Hospital
Authors: A. Sinclair, I. Earnshaw, A. Chowdhury, G. Patel, N. Chopra, E. Merry, G. Soosaipillai, M. Galazi, S. Benafif, A. Wu, C. Sng, Y.N.S. Wong, D. Ottaviani, H. Shaw, A.J.X. Lee, R. Roylance
Journal: Annals of Oncology (2021)
1475P Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
Authors: F. Gardner, Z. Wainberg, C. Fountzilas, N. Bahary, M. Womack, T.M. Mercada, I. Garrido-Laguna, P.M. Peterson, M. Ceccarelli, U. Pelzer
Journal: Annals of Oncology (2021)
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
Authors: Eric J. Lawitz, Diane E. Shevell, Giridhar S. Tirucherai, Shuyan Du, Warner Chen, Uma Kavita, Angie Coste, Fred Poordad, Morten Karsdal, Mette Nielsen, Zachary Goodman, Edgar D. Charles
Journal: Hepatology (2021)

Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct-acting antiviral drug regimens; however, patients with advanced fibrosis have an increased risk for HCC. Heat shock protein 47 (HSP47), a key collagen chaperone, has been implicated in fibrosis development. We evaluated the efficacy and safety of BMS-986263, a lipid nanoparticle delivering small interfering RNA designed to degrade HSP47 mRNA, for the treatment of advanced fibrosis.
1222P A blood-based DNA methylation risk score (RS) for predicting the prognosis of EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC) after first-line TKI treatment
Authors: D. Shi, J. Qin, B. Liu, Y. Yin, B. Zhao, X. Feng, G. Liu, L. Zhai
Journal: Annals of Oncology (2021)
Genomic insight into balancing high yield, good quality, and blast resistance of japonica rice
Authors: Ning Xiao, Cunhong Pan, Yuhong Li, Yunyu Wu, Yue Cai, Yue Lu, Ruyi Wang, Ling Yu, Wei Shi, Houxiang Kang, Zhaobing Zhu, Niansheng Huang, Xiaoxiang Zhang, Zichun Chen, Jianju Liu, Zefeng Yang, Yuese Ning, Aihong Li
Journal: Genome biology (2021)

Abstract Background Balancing the yield, quality and resistance to disease is a daunting challenge in crop breeding due to the negative relationship among these traits. Large-scale genomic landscape analysis of germplasm resources is considered to be an efficient approach to dissect the genetic basis of the complex traits. Central China is one of the main regions where the japonica rice is produced. However, dozens of high-yield rice varieties in this region still exist with low quality or susceptibility to blast disease, severely limiting their application in rice production. Results Here, we re-sequence 200 japonica rice varieties grown in central China over the past 30 years and analyze the genetic structure of these cultivars using 2.4 million polymorphic SNP markers. Genome-wide association mapping and selection scans indicate that strong selection for high-yield and taste quality associated with low-amylose content may have led to the loss of resistance to the rice blast fungus Magnaporthe oryzae . By extensive bioinformatic analyses of yield components, resistance to rice blast, and taste quality, we identify several superior alleles for these traits in the population. Based on this information, we successfully introduce excellent taste quality and blast-resistant alleles into the background of two high-yield cultivars and develop two elite lines, XY99 and JXY1, with excellent taste, high yield, and broad-spectrum of blast resistance. Conclusions This is the first large-scale genomic landscape analysis of japonica rice varieties grown in central China and we demonstrate a balancing of multiple agronomic traits by genomic-based strategy.
A role of serotonin and the insula in vigor: Tracking environmental and physiological resources
Authors: Mattie Tops, Maarten A S Boksem, Jesus Montero-Marin, Dimitri van der Linden
Journal: Behavioral and Brain Sciences (2021)

Abstract We describe a neural monitor of environmental and physiological resources that informs effort expenditure. Depending on resources and environmental stability, serotonergic and dopaminergic neuromodulations favor different behavioral controls that are organized in corticostriatal loops. This broader perspective produces some suggestions and questions that may not be covered by the foraging approach to vigor of Shadmehr and Ahmed (2020).
1406P Survival outcomes in older adults with metastatic gastric and esophageal carcinoma receiving palliative chemotherapy
Authors: M.J. Allen, O. Espin-Garcia, C. Suzuki, E. Panov, L. Ma, B. Yvonne, R. Jang, E. Chen, G. Darling, J. Yeung, C. Swallow, S. Brar, S. Kalimuthu, R. Wong, P. Veit-Haibach, E. Elimova
Journal: Annals of Oncology (2021)
1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy
Authors: C.C. Barron, S. Kuang, M. Makarem, M.J. Elliott, K. Sharma, J. Lee, S. Schmid, A. Rabinovitch, P. Bradbury, G. Liu, F.A. Shepherd, M.S. Tsao, N. Leighl, A. Rose, R. Pezo, M. Doherty, S. Cheng, S.C. Lau, A. Sacher
Journal: Annals of Oncology (2021)
1255P Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Authors: N. Reinmuth, S. Popat, L. Paz-Ares, E. Knowles, A. Hatswell, T. McLean, S. Adrian, B. Gaumond, H. Vioix, P.K. Paik
Journal: Annals of Oncology (2021)
547P Early pharmacokinetic data from a phase I study of SQ3370 in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
Authors: V. Subbiah, V. Bhadri, N. Bui, K. Batty, M. Strach, M. Zakharian, S. Smith, N.A. Yee, S. Srinivasan, M.W. Saville, J.M. Mejía Oneto, A. Guminski
Journal: Annals of Oncology (2021)
1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
Authors: A.K.S. Salama, V. Cheshuk, J. Siveke, A. Berrocal, S.E. Abdullah, S. Lockwood, M.L. McCully, D. Kee
Journal: Annals of Oncology (2021)
1547P Trabectedin in soft-tissue sarcoma patients in Italy: Analysis of real-world data from a national registry
Authors: B. Vincenzi, S. Celant, S. Di Segni, P.P. Olimpieri, A. Comandone, A. Napolitano, R. Sanfilippo, P. Russo, P.G. Casali
Journal: Annals of Oncology (2021)
Urgent Appeal From Hospice Nurses for Pediatric Palliative Care Training and Community
Authors: Katharine E. Brock
Journal: JAMA Network Open (2021)

Amy S. Porter, MD, PhD; Kristina Zalud, MD; Jacob Applegarth, BS; Cameka Woods, MBA, CRA; Melanie Gattas, CRA-RN; Emily Rutt, CPNP-AC; Karen Williams, RN; Justin N. Baker, MD; Erica C. Kaye, MD, MPH
1150TiP A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Authors: K.A. Margolin, R. Korn, M. Farwell, M.A. Postow, D. Hays, I.A. Wilson, W.H. Le
Journal: Annals of Oncology (2021)
1750P Molecular genotyping in refractory thyroid cancers: Results of a European survey
Authors: C. de la Fouchardiere, L. Fugazzola, J. Taylor, M. Appetecchia, N. Besic, A. Bongiovanni, C. Buffet, G. Costante, S. Gay, E. Grande, E. Kapiteijn, J. Krajewska, M. Kroiss, H. Morreau, R. Netea-Maier, R. Peeters, P. Soares, G. Sykiotis, J-Y. Blay, L.D. Locati
Journal: Annals of Oncology (2021)
1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315
Authors: A. Gröschel, B. Passlick, M. Stuschke, P. Christopoulos, M. Reck, C. Grah, A. Groth, A. Hipper, M. Chiabudini, A. Fleitz, M. Jänicke, L. Spring, D.C. Christoph, C. Bernhardt, M. Reiser, M-O. Zahn, M. Sebastian, F. Griesinger, M. Thomas, W.E.E. Eberhardt
Journal: Annals of Oncology (2021)
A multiparametric volumetric quantitative ultrasound imaging technique for soft tissue characterization
Authors: Farah Deeba, Caitlin Schneider, Shahed Mohammed, Mohammad Honarvar, Julio Lobo, Edward Tam, Septimiu Salcudean, Robert Rohling
Journal: Medical Image Analysis (2021)

Quantitative ultrasound (QUS) offers a non-invasive and objective way to quantify tissue health. We recently presented a spatially adaptive regularization method for reconstruction of a single QUS parameter, limited to a two dimensional region. That proof-of-concept study showed that regularization using homogeneity prior improves the fundamental precision-resolution trade-off in QUS estimation. Based on the weighted regularization scheme, we now present a multiparametric 3D weighted QUS (3D QUS)imaging system, involving the reconstruction of three QUS parameters: attenuation coefficient estimate (ACE), integrated backscatter coefficient (IBC) and effective scatterer diameter (ESD). With the phantom studies, we demonstrate that our proposed method accurately reconstructs QUS parameters, resulting in high reconstruction contrast and therefore improved diagnostic utility. Additionally, the proposed method offers the ability to analyze the spatial distribution of QUS parameters in 3D, which allows for superior tissue characterization. We apply a three-dimensional total variation regularization method for the volumetric QUS reconstruction. The 3D regularization involving N planes results in a high QUS estimation precision, with an improvement of standard deviation over the theoretical rate achievable by compounding N independent realizations. In the in vivo liver study, we demonstrate the advantage of adopting a multiparametric approach over the single parametric counterpart, where a simple quadratic discriminant classifier using feature combination of three QUS parameters was able to attain a perfect classification performance to distinguish between normal and fatty liver cases.
Embracing a Trauma-Informed Approach to Patient Care—In With the New
Authors: Jaclyn N. Portelli Tremont, Brian Klausner, Pascal Osita Udekwu
Journal: JAMA Surgery (2021)

This Viewpoint examines the implications of incorporating a broadened definition of trauma—one that includes antecedents of disease and behavior, such as adverse childhood experiences—into the care of surgical patients.